With the advent of KRAS-targeted drugs, including sotorasib, and RET-targeted, pralsetinib (Thein et al., 2021), version 5.2021 of the NCCN guidelines for NSCLC has been amended to indicate the need for KRAS genetic testing. This evidence concerns the gene KRAS and non-small cell lung carcinoma.